The amount of development, regulatory and sales milestone payments paid under the collaboration and license agreements.

No definition available.

Name:	elev_CollaborationAndLicenseAgreementsMilestonePaymentsPaid
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayable
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of development, regulatory and sales milestone payments payable under the collaboration and license agreements for per licensed product.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsMilestonePaymentsPayablePerLicensedProduct
Namespace Prefix:	elev_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The number days of prior written notice to terminate the agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsNoticePeriod
Namespace Prefix:	elev_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty on net sales of licensed products under the collaboration and license agreement.

+ References

No definition available.

+ Details

Name:	elev_CollaborationAndLicenseAgreementsPercentageOfRoyaltyOnNetSalesOfLicensedProducts
Namespace Prefix:	elev_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 55
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479908/805-50-55-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

+ Details

Name:	us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 15
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480123/805-50-15-3

+ Details

Name:	us-gaap_AssetAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_DyaxAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_SelexisAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_AssetPurchaseAgreementRelatingToSeribantumabMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=elev_NIHAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Asset Purchase and License Agreements - (Details) $ in Thousands, € in Millions	1 Months Ended		3 Months Ended		6 Months Ended		12 Months Ended
	May 31, 2019 USD ($)	May 31, 2019 EUR (€)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Asset Acquisition [Line Items]
Research and development			$ 6,551	$ 6,029	$ 12,562	$ 13,321
Dyax
Asset Acquisition [Line Items]
Number of days written prior notice to terminate agreement	90 days	90 days
Selexis
Asset Acquisition [Line Items]
Milestone payments payable \| €		€ 0.2
Number of days written prior notice to terminate agreement	60 days	60 days
Percentage of royalty on net sales of licensed products	1.00%	1.00%
Asset Purchase Agreement relating to Seribantumab
Asset Acquisition [Line Items]
Upfront payment	$ 3,500
Milestone payments payable	54,500
Research and development	3,500
Milestone payments paid					$ 0		$ 0
Maximum \| Dyax
Asset Acquisition [Line Items]
Milestone payments payable	9,300
Maximum \| Selexis
Asset Acquisition [Line Items]
Milestone payments payable, per licensed product \| €		€ 0.9
Maximum \| National Institute of Health
Asset Acquisition [Line Items]
Milestone payments payable	$ 400